Astrazeneca

FromAstraZeneca ([email protected])
Subject (110)Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
Preheader (110)Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
Typography
Arial
Colors
Text Analysis
Body Words195
Subject Words15
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px
X-Spam Score-5.7
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening

Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer

Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
Enhertu granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer